key: cord-0897897-6v9hnmv2
authors: Basar, Rafet; Uprety, Nadima; Ensley, Emily; Daher, May; Klein, Kimberly; Martinez, Fernando; Aung, Fleur; Shanley, Mayra; Hu, Bingqian; Gokdemir, Elif; Nunez Cortes, Ana Karen; Mendt, Mayela; Silva, Francia Reyes; Acharya, Sunil; Laskowski, Tamara; Muniz-Feliciano, Luis; Banerjee, Pinaki P.; Li, Ye; Li, Sufang; Garcia, Luciana Melo; Lin, Paul; Shaim, Hila; Yates, Sean G.; Marin, David; Kaur, Indreshpal; Rao, Sheetal; Mak, Duncan; Lin, Angelique; Miao, Qi; Dou, Jinzhuang; Chen, Ken; Champlin, Richard E.; Shpall, Elizabeth J.; Rezvani, Katayoun
title: Generation of glucocorticoid resistant SARS-CoV-2 T-cells for adoptive cell therapy
date: 2021-07-07
journal: Cell Rep
DOI: 10.1016/j.celrep.2021.109432
sha: eecb0ee203c36f36a4fb540b75a0f7c50cb21ef0
doc_id: 897897
cord_uid: 6v9hnmv2

Adoptive cell therapy with viral-specific T cells has been successfully used to treat life-threatening viral infections, supporting the application of this approach against COVID-19. We expand SARS-CoV-2 T-cells from the peripheral blood of COVID-19-recovered donors and non-exposed controls using different culture conditions. We observe that the choice of cytokines modulates the expansion, phenotype and hierarchy of antigenic recognition by SARS-CoV-2 T-cells. Culture with IL-2/4/7 but not other cytokine-driven conditions result in >1000 fold expansion in SARS-CoV-2 T-cells with a retained phenotype, function and hierarchy of antigenic recognition when compared to baseline (pre-expansion) samples. Expanded CTLs are directed against structural SARS-CoV-2 proteins, including the receptor-binding domain of Spike. SARS-CoV-2 T-cells cannot be efficiently expanded from the peripheral blood of non-exposed controls. Since corticosteroids are used for the management of severe COVID-19, we propose an efficient strategy to inactivate the glucocorticoid receptor gene (NR3C1) in SARS-CoV-2 CTLs using CRISPR-Cas9 gene editing.

Buffy coat collection PBMC co-culture with viral pepmixes (against M, N and S proteins) and cytokine cocktail (IL-2/4/7 or IL-2/7/15) Generation and expansion of SARS-CoV-2 specific T cells

Freezing and generation of biobank of NR3C1 KO SARS-CoV-2 specific T cells remdesivir, lopinavir/ritonavir, and interferon-beta (Beigel et al., 2020; Cao et al., 2020; Casadevall and Pirofski, 2020; Hung et al., 2020; NCT04315948, 2020) . So far, none appear to be curative, making it critical to develop novel therapeutic strategies.

SARS-CoV-2 infection is characterized by profound T-lymphopenia associated with a dysregulated/excessive innate response, thought to be the underlying mechanism for acute respiratory distress syndrome (ARDS), the major cause of morbidity and mortality with this virus (Fathi and Rezaei, 2020; Mehta et al., 2020) . Recent studies from patients with COVID-19 point to an important role for T cell adaptive immunity in protection and clearance of the virus (Braun et al., 2020) , with T cell responses documented against the structural SARS-CoV-2 viral proteins spike (S), membrane (M) and nucleocapsid (N) (Grifoni et al., 2020; Ni et al., 2020; Sekine et al., 2020; Thieme et al., 2020) . Indeed, in preclinical models of SARS-CoV-1 infection, adoptive transfer of virus-specific T cells (VSTs) was shown to be curative in infected mice, supporting the use of adoptive cell therapy (ACT) in coronavirus-related infection. ACT with allogeneic cytotoxic T-lymphocytes (CTLs) has been successfully used to treat other severe viral infections, such as cytomegalovirus (CMV), adenovirus, BK virus, Epstein-Barr virus and human herpes virus 6 in immunosuppressed patients, with responses ranging from 60-100% (Haque et al., 2007; Muftuoglu et al., 2018; O'Reilly et al., 2016; Tzannou et al., 2017) . Thus, ACT may be an attractive approach for the management of COVID-19related disease. However, many patients with severe COVID-19 receive corticosteroids which, due to their lymphocytotoxic effects, limit the efficacy of ACT. Here, we describe a novel approach for the generation of highly functional and steroid-resistant SARS-CoV-2 reactive T cells for the immunotherapy of patients with COVID-19.

J o u r n a l P r e -p r o o f 4

Our group has previously reported the feasibility of generating VSTs from the peripheral blood (PB) of healthy donors for ACT (Muftuoglu et al., 2018) . Here, we utilized this approach to derive and expand SARS-CoV-2 specific T-cells. Briefly, PBMCs from 10

CoV19 

We next interrogated the functional phenotype of the ex vivo expanded SARS-CoV-2

CTLs. Since IL-2/4/7 and IL-2/7/15 resulted in the best cell expansion, we focused our analysis on SARS-CoV-2 CTLs generated using these two conditions. Both culture conditions supported expansion of effector memory (EM) and central memory (CM) T cells although the use of IL-2/7/15 resulted in expansion of CM T cells ( Figure 1C) .

Previous studies in patients with severe COVID-19 have reported the presence of T cells with an exhausted phenotype and reduced polyfunctionality (Chen et al., 2020;  J o u r n a l P r e -p r o o f 5 Zheng et al., 2020a Zheng et al., , 2020b . Thus, we performed a comprehensive single cell analysis of expanded SARS-CoV-2 CTLs from 8 recovered donors using mass cytometry.

Phenotypic assessment of SARS-CoV-2 reactive T-cells expanded with IL-2/4/7 or IL-2/7/15 (identified based on their ability to produce IFN- in response to ex vivo stimulation with a mixture of S, M and N peptide libraries) revealed that SARS-CoV-2 specific CTLs are polyfunctional based on their ability to secrete multiple cytokines, including IFN-, TNF- and MIP-1 (cluster 32; Figure 1D and 1E) and chemokine receptors that support trafficking to the lungs such as CXCR3 and CCR4 ( Figure S1 ).

Moreover, ex vivo expanded SARS-CoV-2 CTLs did not express high levels of inhibitory/checkpoint molecules, thus arguing against an exhausted phenotype (cluster 32; Figure 1F ). Indeed, analysis of functional markers revealed a cytotoxic Th1 phenotype, characterized by expression of IFN-, TNF-, CD107a and granzyme B

(GrB) (Figure 1F ), and the ability to kill SARS-CoV-2 pepmix-loaded autologous PBMCs by annexin V killing assay ( Figure 1G ). These data indicate direct antiviral killing capacity of our CTLs, although we are unable to discriminate between TNF- or perforin dependent -killing given the longer duration of the cytotoxicity assay used in our experiment. SARS-CoV-2 CTLs did not produce significant amounts of IL-2 in response to antigenic stimulation. Single cell phenotypic comparison of SARS-CoV-2 CTLs expanded using the two different culture conditions did not reveal major differences in the expression patterns of activation and functional markers between these two groups ( Figure 1F ). However, cells expanded in the presence of IL-2/4/7 expressed lower levels of some exhaustion markers such as TIM3 and LAG3 compared to cells expanded with IL-2/7/15 ( Figure 1H ). Taken together, these data support the notion that polyfunctional, non-exhausted T cells capable of reacting against SARS-CoV-2 antigens can be expanded from the PB of CoV-RDs.

We also performed a multiplex analysis to measure cytokines in supernatants collected from cultures of SARS-CoV-2 CTLs with SARS-CoV-2 antigens (n=4 samples for each of the culture conditions-IL-2/4/7 and IL-2/7/15). As expected, the expanded SARS-CoV-2 CTLs released effector cytokines such as IFN-, TNF-, MIP-1β in response to antigenic stimulation. Notably, they did not produce cytokines such as IL-6, IL-1, or IL-J o u r n a l P r e -p r o o f 6 10 that could contribute to a higher risk of toxicity or cytokine release syndrome (CRS) ( Figure S2 ). (Figure 2A) . In sum, for both IL-2/4/7 and IL-2/7/15 culture settings, seven lines were directed against M + N + S, one line was directed against S + N, and no line reacted to M and N in the absence of S. There was no significant expansion of CTLs in response to the non-structural proteins or the structural E protein.

When we considered the CD4+ and CD8+ T cell responses separately, we found that the response of CD4+ T cells to individual SARS-CoV-2 antigens followed a pattern similar to that observed in the overall CD3+ T cell population. Interestingly, however, CD8+ T cell responses were mostly directed against the N protein, irrespective of the cytokine cocktail used for SARS-CoV-2 CTL expansion ( Figure 2B , Table 1 ).

Peptides derived from the C-terminus of the S protein have higher homology with the S glycoprotein of human endemic "common cold" coronaviruses; in contrast, the Nterminus of the S protein includes peptides from the receptor-binding domain (the target of neutralizing antibodies) that are more specific to SARS-CoV-2 (Braun et al., 2020; Walls et al., 2020) . Our expanded CD4+ and CD8+ SARS-CoV-2 CTLs were capable of J o u r n a l P r e -p r o o f 7 reacting to epitopes found on the N-terminus or the C-terminus or the S protein (Peptide pools 1 and 2 respectively), indicating their specificity for the receptor binding domain (RBD) of SARS-CoV-2 ( Figure 2C , Tables 2, S4 and S5).

Culture with IL-2/4/7 results in preferential expansion of T cells against the N-

Since the choice of cytokines used to expand SARS-CoV-2 T-cells modulates the hierarchy of antigenic response, we compared the T cell response against S (S1 and S2), M and N proteins of SARS-CoV-2 in PB samples at baseline (prior to expansion)

with that observed in paired expanded CTLs from Cov-RDs.

At baseline (pre-expansion), the responses were mostly CD4 dominant ( Figure 3A) , and directed against the S protein (median 0.21%, range 0.02%-0.56%), followed by N (median 0.15%, range 0.01-0.33%) and M (median 0.11%, range 0.01-0.24%) ( Figure   3B ), indicating an immunogenic dominance for S protein HLA class II epitopes. We did not detect measurable responses against non-structural proteins (data not shown).

Following expansion, culture with IL-2/4/7 maintained the hierarchy of CD4+ T cell response toward S protein, (Figures 2B, 3C , and 3D), with a greater proportion of T cells directed against S1, while culture with IL-2/7/15 favored a response toward M protein ( Figures 2B, 3C , and 3D). Expansion with IL-2/4/21 and IL-2/7/21 yielded very low numbers of CTLs, most of which were CD4+. Interestingly, the pattern of antigenic response for cells cultured using these two conditions differed from that observed for IL-2/4/7 and was similar to IL-2/7/15, in that the majority of CD4+ CTLs reacted instead to M and N proteins ( Figures S3A) . For CTLs that did show a response to S protein, further analysis detected no particular pattern of reactivity to either terminus of the protein ( Figure S3B ).

Furthermore, we found a significant correlation (p=0.002, R 2 =0.82) between the spike protein IgG antibody titer measured in plasma from recovered donors and the absolute number of SARS-CoV-2 specific T cells following expansion with IL-2/4/7, but not with the IL-2/7/15 cytokine cocktail ( Figure S4A ). However, there was no correlation J o u r n a l P r e -p r o o f 8 between the spike protein IgG antibody titer and the absolute number of SARS-CoV-2 T cells prior to ex vivo expansion at baseline (p=0.52, R 2 =0.07) ( Figure S4B ).

Nonetheless, we recognize that the correlation observed following expansion could be skewed by the data from a single patient who represents an outlier and that further studies with larger cohorts are needed to confirm this trend.

These data indicate that the antigenic skewing can be driven both by the immunodominance of the protein and by the culture conditions and support the use of IL-2/4/7 for the expansion of SARS-CoV-2 T-cells for clinical use.

Recent reports indicate the presence of SARS-CoV-2 T cells in the PB of healthy donors (HD) not exposed to COVID-19 (Braun et al., 2020; Pia, 2020) . Thus, we asked if SARS-CoV-2 T-cells can be expanded from the PB of HD and whether they have a similar pattern of SARS-CoV-2 recognition as those generated from Cov-RDs. PBMC from 5 HDs were expanded using the same protocol as for Cov-RDs. We achieved only a modest expansion of CTLs recognizing SARS-CoV-2 antigens over a 14-day culture period, with a median 20.37-fold increase (range, 2.85 -41.84) for IL-2/4/7 culture condition and 21.49-fold increase (range, 4.00 -53.95) for IL-2/7/15 culture condition ( Figure 4A ). The frequencies of SARS-CoV-2 CTLs from the PB of healthy donors after 14 days of culture were significantly lower than those achieved with PB from Cov-RDs ( Figure 4B ). At baseline (pre-expansion), assessment of IFN-γ production and CTL frequencies suggested that in healthy donors responses were directed mostly against the N protein (median 0.13%, range 0.03%-0.37%), followed by S (median 0.10%, range 0.04-0.12%) and M (median 0.09%, range 0.01-0.75%) ( Figure S5A ). Culture in the presence of either cytokine cocktail could skew the response towards S, albeit at much lower frequencies than that observed with Cov-RDs ( Figure S5B , Tables S6 and S7). We did not find any particular pattern of antigenic response in the CD4 and CD8 compartments ( Figure S5B , Tables S6 and S7). Expansion was not successful in IL- The effector phenotype predicts for the capacity to mediate early viral clearance, while the central memory T-cells persist and provide long-term immunity after adoptive transfer (Powell et al., 2005) . Indeed, our group and others have confirmed that the adoptive infusion of VSTs with a predominantly CD4+ effector memory phenotype results in successful eradication of severe viral infections such as JCV, BKV and adenovirus (Heslop et al., 2010; Leen et al., 2011; Muftuoglu et al., 2018; Olson et al., 2021) . We also investigated the functional state of SARS-CoV-2 T cells based on their ability to produce one or more cytokines in response to ex vivo stimulation with SARS-CoV-2 antigens. Polyfunctionality is defined as the production of multiple cytokines by T cells and is associated with protective immune responses to viruses and vaccines (Minton, 2014) . We confirmed that SARS-CoV-2 T-cells were polyfunctional with a predominantly Th1 phenotype and were capable of killing antigen-loaded targets.

T cells derived from patients with severe COVID-19 have been reported to express multiple inhibitory molecules (Song et al., 2020), raising concerns that following ex vivo expansion, they may have an exhausted phenotype with poor effector function and replicative senescence. In our study, T cells from COVID-19-recovered individuals did J o u r n a l P r e -p r o o f 11 not have an exhaustion phenotypic signature following in vitro expansion, and retained their functional phenotype.

SARS-CoV-2 neutralizing antibodies are directed against the RBD within the N-terminus of the S glycoprotein. Peptides derived from this region of the protein are believed to be specific to SARS-CoV-2, while peptides from the C-terminus are shared with other betacoronaviruses (Braun et al., 2020) . We showed that expanded SARS-CoV-2 T-cells from CoV-RD were capable of recognizing epitopes from both the N-and C-terminus of the S glycoprotein, indicating specificity for the SARS-CoV-2 virus. In addition, expanded CTLs reacted against N and M proteins, which are reportedly also shared among different beta-coronaviruses (Patrick et al., 2006) . The specific antigens that drive an effective and protective T-cell response against SARS-CoV-2 are not yet known. They may be proteins that are shared with other beta-coronaviruses, or they may be unique to SARS-CoV-2 (e.g. RBD) or may likely be a combination of both.

Cytokines can modulate the phenotype of T cells by activating different signaling pathways. We tested different combinations of cytokines, including IL-2, IL-4, IL-7, IL15

and IL-21 to identify the optimal conditions to promote expansion of SARS-CoV-2 Tcells with a memory phenotype and without evidence of exhaustion. While IL-2, IL-4, IL-7 and IL-15 support expansion of central and effector memory T-cells, (Clénet et al., 2017; Geginat et al., 2001) , with IL-2, IL-7 and IL-15 driving proliferation through STAT5

signaling (Drake et al., 2016) , in vitro culture with IL-21 facilitates the generation of memory stem-like T cells (Chen et al., 2018) . Since both CD4 and CD8 T cells are involved in successful antiviral response, we also investigated whether cytokines would support expansion of both subsets. We observed that cocktails including IL-2/4/7 or IL- previous studies reporting that the effect of IL-21 to augment the antigen-specific T-cell response is limited to the naive and not the memory T cell population (Li et al., 2005) .

CRS is a major complication of COVID-19 (Moore and June, 2020) and is caused by the production of inflammatory cytokines such as IL-6 by virus-infected myeloid cells. The inflammatory milieu overstimulates cells of the innate and adaptive immune system which in turn contribute to the observed cytokine storm (Kang et al., 2019) . Therefore, a legitimate concern with our approach is that the adoptively infused SARS-CoV-2 T-cells, which also include a small percentage of Th2 and Th17 subsets, could amplify CRS and worsen the patient's condition (Hotez et al., 2020; Wu and Yang, 2020) . However, we believe that ACT for COVID-19 is unlikely to worsen CRS as the adoptively infused

CTLs will target and kill SARS-CoV-2 infected myeloid cells, thus breaking the vicious cycle driving the cytokine storm. Furthermore, CRS is not unique to beta-coronavirus infections and has been reported with other viral infections such as CMV, EBV and adenovirus (Humar et al., 1999; McLaughlin et al., 2018; Ramos-Casals et al., 2014) where adoptive cell therapy with virus-specific CTLs has been used to treat hundreds of In summary, adoptive transfer of SARS-CoV-2 T-cells may be a suitable therapeutic strategy for treatment of patients with COVID-19.

Our study evaluated the cytotoxic effect of SARS-CoV-2 T cells using well validated in vitro assays. We could not test the efficacy of our expanded SARS-CoV-2 T cells in vivo because a robust mouse model of human COVID-19 is not readily available. We also recognize that our study lacks patient data, however a phase I/II clinical trial is currently underway to assess the feasibility, safety and efficacy of our off-the-shelf SARS-CoV-2 T-cells in patients with mild to moderate COVID-19 disease (NCT04742595). Table 1 

CD3 % CD4 % CD8 % S1 S2 S1 S2 S1 S2 

 The data will be available from the lead contact upon request.

 This paper does not report original code.

 Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

Buffy coat units were processed from 500mL of whole blood collected from each of the 10 COVID-19 recovered donors (CoV-RD) and 20 mL of peripheral blood from 5 healthy donors were collected under local Institutional Review Board approved protocols (Lab02-0630 and PA13-0647) and following informed consent. All donors were 18 years or older and were recruited without consideration of disease severity, race, ethnicity or gender. All CoV-RD had recovered from proven symptomatic COVID-19 confirmed by a positive test for SARS-CoV-2. At the time of blood collection, all were asymptomatic for at least 14 days and had a negative PCR test, confirming full recovery.

Blood from Cov-RD was collected in heparin-coated blood bags and stored at room temperature prior to processing for peripheral blood mononuclear cell (PBMC) isolation.

PBMCs were isolated by density-gradient sedimentation using Ficoll-Paque 

IgM and IgG responses against nucleocapsid, S1 receptor-binding domain (RBD), S1S2, S2, S1, OC43, HKU1, NL63 Nucleoprotein, and 229E Spike derived from SARS-CoV-2 and other human coronaviruses were performed at Genalyte (Austin, TX) CLIAcertified laboratory using plasma from convalescent patients. following the manufacturer's instructions.

Isolated PBMC from CoV-RD and HD were pulsed with a SARS-CoV-2 pepMix (JPT, Germany) comprising the entire length of the structural (S, M, N, E) and non-structural (AP3A, Y14, NS6, NS7a, NS7B, NS8, ORF9B and ORF10) proteins at a concentration of 1 µg/ml per peptide. Cells were cultured in complete media with 5% human AB serum and supplemented with four different cytokine cocktails: IL-2 (50 IU/ml), IL-4 (60 ng/ml) and IL-7 (10 ng/ml) vs. IL-2 (50 IU/ml), IL-7 (10 ng/ml) and IL-15 (10 ng/ml) vs.

IL-2 (50 IU/ml), IL-4 (60 ng/ml) and IL-21 (30 ng/ml) vs. IL-2 (50 IU/ml), IL-7 (10 ng/ml) and IL-21 (30 ng/ml) every 3 days. After 14 days of expansion, the frequencies of SARS-CoV-2 specific T-cells were determined by intracellular cytokine staining.

A panel of 40 metal-tagged antibodies was used for the in-depth characterization of SARS-CoV-2 reactive T-cells (Table S1 ). All unlabeled antibodies were purchased in carrier-free form (Fluidigm) and conjugated in-house with the corresponding metal tag using Maxpar X8 polymer per the manufacturer's instructions (Fluidigm) and as previously described (Muftuoglu et al., 2018) . Briefly, thawed PBMCs were rested overnight at 37 o C / 5% CO2 and stained with a freshly prepared antibody mix against cell surface markers for 30 minutes at room temperature on a shaker (100 rpm 

To detect GR protein expression, CTLs were lysed in lysis buffer (IP Lysis Buffer; Pierce

Biotechnology Inc) supplemented with protease inhibitors (Complete Mini, EDTA-free Cocktail tablets; Roche Holding) and incubated for 30 minutes on ice. Protein concentration was determined by the bicinchoninic acid (BCA) assay (Pierce Biotechnology Inc). The following primary antibodies were used: GR (clone D6H2L) XP rabbit monoclonal antibody and β-actin antibody (clone 8H10D10); both antibodies were obtained from Cell Signaling Technology. Blots were imaged using a G:BOX gel documentation system and GeneSys software (Syngene).

Statistical significance was assessed with Prism 9.0 software (GraphPad Software, Inc.). Means were compared using unpaired t-test, paired t-test, one-way ANOVA, or two-way ANOVA as needed. The Tukey correction was used for correction of multiple comparisons. For correlation analysis, R squared simple linear regression was used.

Graphs represent mean and standard deviation (SD). A P ≤ 0.05 was considered to be statistical significance. When analyzing variables with more than 2 categories, P values were adjusted for multiple comparisons. The statistical details are found in the figure legends. J o u r n a l P r e -p r o o f 

Large-scale GMPcompliant CRISPR-Cas9-mediated deletion of the glucocorticoid receptor in multivirusspecific T cells

T cells for viral infections after allogeneic hematopoietic stem cell transplant

Presence of SARS-CoV-2 reactive T cells in COVID-19 patients and healthy donors

A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19

The convalescent sera option for containing COVID-19

Clinical and immunological features of severe and moderate coronavirus disease 2019

Adoptive Transfer of Interleukin-21-stimulated Human CD8+ T Memory Stem Cells Efficiently Inhibits Tumor Growth

Peripheral human CD4+CD8+ T lymphocytes exhibit a memory phenotype and enhanced responses to IL-2, IL-7 and IL-15

Interleukins 7 and 15 Maintain Human T Cell Proliferative Capacity through STAT5 Signaling

Adoptive T-cell immunotherapy from third-party donors: Characterization of donors and set up of a Tcell donor registry

Lymphopenia in COVID-19: Therapeutic opportunities

Cytokine-driven Proliferation and Differentiation of Human Naive, Central Memory, and Effector Memory CD4+ T Cells

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: Results of a phase 2 multicenter clinical trial

Long-term outcome of EBVspecific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients

The potential role of Th17 immune responses in coronavirus immunopathology and vaccine-induced immune enhancement

Elevated serum cytokines are associated with cytomegalovirus infection and disease in bone marrow transplant recipients

Triple combination of interferon beta-1b, lopinavirritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised

Targeting Interleukin-6 Signaling in Clinic

Most Closely HLA-Matched Allogeneic Virus Specific Cytotoxic T-Lymphocytes (CTL) to Treat Persistent Reactivation or Infection With Adenovirus, CMV and EBV After Hemopoietic Stem Cell Transplantation (HSCT)

IL-21 Influences the Frequency, Phenotype, and Affinity of the Antigen-Specific CD8 T Cell Response

Adoptive T Cell Therapy for Epstein-Barr Virus Complications in Patients With Primary Immunodeficiency Disorders

COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet

Mechanisms of T cell polyfunctionality

Cytokine release syndrome in severe COVID-19

Allogeneic BK Virus-Specific T Cells for Progressive Multifocal Leukoencephalopathy

Trial of Treatments for COVID-19 in Hospitalized Adults

Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals

Third-party BK virus specific cytotoxic T lymphocyte therapy for hemorrhagic cystitis following allotransplantation

Virusspecific T-cell banks for "off the shelf" adoptive therapy of refractory infections

An Outbreak of Human Coronavirus OC43 Infection and Serological Cross-reactivity with SARS Coronavirus

SARS-CoV-2-reactive T cells in patients and healthy donors

Transition of late-stage effector T cells to CD27+ CD28 + tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy

Adult haemophagocytic syndrome

Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19

The SARS-COV-2 T-Cell Immunity is Directed Against the Spike, Membrane, and Nucleocapsid Protein and Associated with COVID 19 Severity. SSRN Electronic Journal

Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation

Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

TCF1(+) hepatitis C virusspecific CD8(+) T cells are maintained after cessation of chronic antigen stimulation

TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib

Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients

Functional exhaustion of antiviral lymphocytes in COVID-19 patients

R package cytofkit (v1.11.3) Chen et.al. (2016) . https://github.com/Jinmiao ChenLab/cytofkit R package Rtsne (v0.15) Krijthe ( 

Further information and requests may be directed to and will be fulfilled by the Lead Contact Katayoun Rezvani (KRezvani@mdanderson.org)

All requests for data and materials will be reviewed by MD Anderson Cancer Center to verify if the request is subject to any intellectual property or confidentiality obligations.Any data and materials that can be shared by the corresponding author will be released freely or via a Material Transfer Agreement if deemed necessary.